Key terms
About CRNX
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CRNX news
May 14
7:17am ET
Cantor Fitzgerald Remains a Buy on Crinetics Pharmaceuticals (CRNX)
May 14
5:50am ET
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Wave Life Sciences (WVE) and Intellia Therapeutics (NTLA)
May 14
5:10am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
May 13
10:09am ET
Crinetics participates in a conference call with Cantor Fitzgerald
May 13
7:55am ET
Oppenheimer Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
May 10
2:35pm ET
Buy Rating for Crinetics Pharmaceuticals: Strong Financials and Promising Clinical Data
May 10
6:48am ET
Crinetics price target raised to $70 from $68 at Citi
May 10
6:28am ET
Buy Rating Affirmed for Crinetics Pharmaceuticals on Strong Drug Pipeline and Market Potential
May 09
4:50pm ET
Crinetics reports Q1 EPS (93c), consensus (81c)
May 08
5:12pm ET
Crinetics Pharmaceuticals Showcases Research at ENDO 2024
May 07
7:50am ET
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Pliant Therapeutics (PLRX) and Crinetics Pharmaceuticals (CRNX)
Apr 30
5:55am ET
Crinetics management to meet with Piper Sandler
Apr 29
4:55am ET
Crinetics management to meet with Piper Sandler
Apr 26
6:51am ET
Crinetics management to meet with Piper Sandler
Apr 05
10:40am ET
Biotech Alert: Searches spiking for these stocks today
Apr 04
5:02pm ET
Crinetics Pharmaceuticals Launches New Deferred Compensation Plan
Mar 25
4:55am ET
JMP Securities biotech analysts to hold an analyst/industry conference call
Mar 22
5:12pm ET
JMP Securities biotech analysts to hold an analyst/industry conference call
Mar 22
11:33am ET
Biotech Alert: Searches spiking for these stocks today
Mar 21
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Mar 21
2:36am ET
Buy Rating Affirmed for Crinetics Pharmaceuticals on Paltusotine’s Clinical Success and Market Potential
Mar 21
2:15am ET
Buy Rating Affirmed for Crinetics Pharmaceuticals Amid Impressive Paltusotine Trial Results
Mar 20
8:00am ET
Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Tyra Bioscience (TYRA) and Crinetics Pharmaceuticals (CRNX)
Mar 20
7:43am ET
Crinetics price target raised to $55 from $54 at Oppenheimer
Mar 20
6:13am ET
Crinetics price target raised to $80 from $60 at JMP Securities
Mar 20
6:04am ET
Crinetics price target raised to $60 from $50 at H.C. Wainwright
Mar 20
6:02am ET
3 Best Stocks to Buy Now, 3/20/2024, According to Top Analysts
Mar 19
4:16pm ET
JonesResearch ups Crinetics target, sees more room to run for shares
Mar 19
4:08pm ET
Crinetics files to sell 8.33M shares of common stock for holders
Mar 19
12:25pm ET
Paltusotine: A Potential Game-Changer in Acromegaly Treatment, Analyst Recommends Buy
Mar 19
8:40am ET
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB)
No recent press releases are available for CRNX
CRNX Financials
Key terms
Ad Feedback
CRNX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CRNX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range